DE602004018284D1 - Mutante vesicular stomatitis viren und deren verwendungen - Google Patents

Mutante vesicular stomatitis viren und deren verwendungen

Info

Publication number
DE602004018284D1
DE602004018284D1 DE602004018284T DE602004018284T DE602004018284D1 DE 602004018284 D1 DE602004018284 D1 DE 602004018284D1 DE 602004018284 T DE602004018284 T DE 602004018284T DE 602004018284 T DE602004018284 T DE 602004018284T DE 602004018284 D1 DE602004018284 D1 DE 602004018284D1
Authority
DE
Germany
Prior art keywords
vesicular stomatitis
stomatitis viruses
mutant
mutant vesicular
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004018284T
Other languages
English (en)
Inventor
John C Bell
Brian D Lichty
David F Stojdl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ottawa Health Research Institute
Wellstat Biologics Corp
Original Assignee
Ottawa Health Research Institute
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Health Research Institute, Wellstat Biologics Corp filed Critical Ottawa Health Research Institute
Publication of DE602004018284D1 publication Critical patent/DE602004018284D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602004018284T 2003-03-27 2004-03-29 Mutante vesicular stomatitis viren und deren verwendungen Expired - Lifetime DE602004018284D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45759103P 2003-03-27 2003-03-27
PCT/CA2004/000460 WO2004085658A1 (en) 2003-03-27 2004-03-29 Mutant vesicular stomatitis viruses and use thereof

Publications (1)

Publication Number Publication Date
DE602004018284D1 true DE602004018284D1 (de) 2009-01-22

Family

ID=33098236

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004018284T Expired - Lifetime DE602004018284D1 (de) 2003-03-27 2004-03-29 Mutante vesicular stomatitis viren und deren verwendungen

Country Status (13)

Country Link
EP (2) EP2039773B1 (de)
JP (4) JP2007524363A (de)
CN (1) CN1788088B (de)
AT (2) ATE417115T1 (de)
AU (1) AU2004223808B2 (de)
CA (1) CA2520279C (de)
DE (1) DE602004018284D1 (de)
DK (1) DK1606411T3 (de)
ES (1) ES2319424T3 (de)
IL (1) IL171133A (de)
MX (1) MXPA05010260A (de)
NZ (1) NZ542902A (de)
WO (2) WO2004085658A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1769433B (zh) * 2004-11-04 2011-03-16 张庆勇 重组水疱性口炎病毒及其应用
CN100341571C (zh) * 2005-09-16 2007-10-10 孙介光 一种治疗肿瘤的药物及该药物在制备治疗肿瘤药物中应用
EP2349296B1 (de) * 2008-08-21 2017-04-05 Ottawa Hospital Research Institute Manipulierte synergistische onkolytische virensymbiose
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
JP5675789B2 (ja) * 2009-06-08 2015-02-25 ザ ユニバーシティー オブ ウェスタン オンタリオＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｗｅｓｔｅｒｎ Ｏｎｔａｒｉｏ 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型
US20110014228A1 (en) * 2009-06-15 2011-01-20 New York University Il23 modified viral vector for recombinant vaccines and tumor treatment
US20120171246A1 (en) * 2009-09-10 2012-07-05 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
CN102486474B (zh) * 2010-12-06 2014-05-28 北京大学人民医院 干扰素治疗慢性丙型肝炎转归预测蛋白芯片
JP6309274B2 (ja) * 2011-03-11 2018-04-11 ターンストーン・リミテッド・パートナーシップ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
KR101989978B1 (ko) * 2011-12-23 2019-06-17 더 유니버시티 오브 웨스트 온타리오 프라임 부스트 백신용 수포성 구내염 바이러스
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
RU2705556C2 (ru) 2012-12-21 2019-11-07 Келверум Инк. Нереплицируемые происходящие от вирусов частицы и их применение
WO2014198003A1 (en) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute Compositions and methods for enhancing virus replication
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
CN105087645A (zh) * 2015-08-04 2015-11-25 上海交通大学 M蛋白三氨基酸位点突变的猪用vsv病毒载体构建和应用
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018075978A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
EP3596116B1 (de) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1-variante immunmodulatorische proteine und verwendungen davon
KR20190141146A (ko) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l2 변이체 면역조절 단백질 및 그의 용도
EP3624825A4 (de) * 2017-05-19 2021-03-10 Georgia State University Research Foundation, Inc. Rekombinantes onkolytisches virus
BR112020007542A2 (pt) 2017-10-18 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019183802A1 (zh) * 2018-03-27 2019-10-03 苏州奥特铭医药科技有限公司 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
CN110305198B (zh) * 2018-03-27 2021-01-29 睿丰康生物医药科技(浙江)有限公司 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
EA202000353A1 (ru) 2018-06-04 2022-01-14 Калиди Биотерапьютикс, Инк. Основанные на клетках носители для потенциализации вирусной терапии
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3116192C (en) 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
EP3884041A2 (de) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Verfahren zur expansion des subsets von natürlichen killer (nk)-tellen und verwandte zusammensetzungen und verfahren
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
CN111494432A (zh) * 2019-01-31 2020-08-07 惠君生物医药科技(杭州)有限公司 一种用于治疗肿瘤或癌症的药物组合物及其应用
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2022524951A (ja) 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
CN111662883A (zh) * 2019-03-06 2020-09-15 惠君生物医药科技(杭州)有限公司 一种制备及纯化溶瘤病毒的方法及重组溶瘤弹状病毒
CN110305850A (zh) * 2019-05-15 2019-10-08 苏州奥特铭医药科技有限公司 一种利用293细胞生产制备溶瘤病毒的方法
CN111939262B (zh) * 2019-05-17 2021-09-17 睿丰康生物医药科技(浙江)有限公司 一种治疗肿瘤或癌症的药物组合物和其应用
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
US20230149536A1 (en) * 2020-04-17 2023-05-18 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
AU2021258194A1 (en) 2020-04-22 2022-11-24 Indapta Therapeutics, Inc. Natural killer (NK) cell compositions and methods for generating same
CN111467489B (zh) * 2020-05-12 2022-06-03 上海荣瑞医药科技有限公司 一种治疗肿瘤的药物
CN111286493B (zh) 2020-05-12 2020-10-27 上海荣瑞医药科技有限公司 一种溶瘤病毒疫苗及其与免疫细胞联合治疗肿瘤的药物
WO2022147480A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Oncolytic virus encoding sialidase and multispecific immune cell engager
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
CN115612674B (zh) * 2021-07-14 2026-01-30 上海荣瑞医药科技有限公司 一种溶瘤病毒及其用途
CN115948352B (zh) * 2022-11-29 2025-09-23 浙江迪福润丝生物科技有限公司 一种水泡性口炎病毒的致弱方法及致弱病毒株和应用
WO2025097249A1 (en) * 2023-11-08 2025-05-15 Genvira Biosciences Inc. Oncolytic vaccinia virus

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US6022726A (en) 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
AU751259B2 (en) 1997-12-12 2002-08-08 Onyx Pharmaceuticals, Inc. Selective killing and diagnosis of p53+ neoplastic cells
JP4544497B2 (ja) 1997-12-22 2010-09-15 ユニバーシティ オブ テネシー リサーチ ファウンデーション 異種融合タンパク質を有する組変えラブドウイルス
DE69937999T2 (de) 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
IL148621A0 (en) * 1999-09-17 2002-09-12 Pro Virus Inc Oncolytic virus
EP1254213A2 (de) 2000-01-26 2002-11-06 Boehringer Ingelheim Vetmedica Gmbh Rekombinante attenuation von prrsv
DE10143813A1 (de) 2001-09-06 2003-04-10 Boehringer Ingelheim Vetmed Infektiöser Rindervirusdiarrhoe-Virusklon
AU2003268505A1 (en) * 2002-09-09 2004-03-29 University Of Tennessee Research Foundation Recombinatant mutants of rhabdovirus and methods of use thereof

Also Published As

Publication number Publication date
ATE417115T1 (de) 2008-12-15
JP2007215547A (ja) 2007-08-30
HK1077084A1 (en) 2006-02-03
EP2039773B1 (de) 2011-12-28
WO2004085659A3 (en) 2004-12-09
AU2004223808B2 (en) 2009-03-26
EP2039773A1 (de) 2009-03-25
WO2004085659A2 (en) 2004-10-07
JP2007524363A (ja) 2007-08-30
MXPA05010260A (es) 2006-03-17
ATE539162T1 (de) 2012-01-15
HK1127370A1 (en) 2009-09-25
EP1606411A1 (de) 2005-12-21
JP2011103897A (ja) 2011-06-02
WO2004085658A1 (en) 2004-10-07
CA2520279C (en) 2012-09-04
JP2013247959A (ja) 2013-12-12
EP1606411B1 (de) 2008-12-10
NZ542902A (en) 2007-06-29
CN1788088A (zh) 2006-06-14
AU2004223808A1 (en) 2004-10-07
IL171133A (en) 2011-11-30
ES2319424T3 (es) 2009-05-07
CN1788088B (zh) 2012-09-26
CA2520279A1 (en) 2004-10-07
DK1606411T3 (da) 2009-03-30

Similar Documents

Publication Publication Date Title
DE602004018284D1 (de) Mutante vesicular stomatitis viren und deren verwendungen
CY1122841T1 (el) Πολυαλκυλενικες πολυμερικες ενωσεις και χρησεις αυτων
FR20C1016I1 (de)
CY1107524T1 (el) 9- υποκατεστημeνα συστατικa της μινοκυκλiνης
EP1032269A4 (de) Behandlung von neoplasmen mit viren
DK0773785T3 (da) Behandling af cancer ced hjælp af HSV-mutant
DE60329367D1 (de) Verwendung bei der bekämpfung von hepatitis c virusinfektion
SE9704171L (sv) Hydroxifenyltriaziner
CY1112140T1 (el) Ανασυνδυασμενοι ιοι γριππης για εμβολια και γονιδιακη θεραπεια
ATE73663T1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
DE60329287D1 (de) Boehmitteilchen und diese enthaltende polymermaterialien
BG100665A (en) Cleaning arrangement including filters and ultraviolet radiation
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
BR0010600A (pt) Método para inativação de cisto de giardia e cryptosporidium usando-se luz ultravioleta
CY1115524T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εναντι της ανθρωπινης il-4
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
DE60033043D1 (de) Modifizierte pflanzenviren und deren verwendungsmethoden
NO20023833D0 (no) Modifiserte cytokiner for anvendelse i cancerterapi
EP1498668A4 (de) Wärmequelleneinheit von klimaanlage und klimaanlage
DE69426799D1 (de) Lichtquelle mit doppeltem Ausgang und hohem Wirkungsgräd
DK0505763T3 (da) Vandigt desinfektionsmiddel, dets anvendelse til inaktivering af hepatitis-B-vira, bakterielle sporer og legionella pneumophila samt desinfektionsfremgangmåder
SE8903003D0 (sv) Novel medical use
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition